Search

315 results for "driving".

Research summaries 292

Showing the best 200 of 292, 151–160, page 16 of 20. Filter these by subject, year and score in the research library →

1. Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/hemispheric-asymmetry-of-tau-pathology-is-related-to-asymmetric-40913038

   … However, the factors driving this asymmetry remain poorly understood. Here we explore whether tau asymmetry is linked to i) reduced inter-hemispheric brain connectivity (potentially restricting tau spread), or ii) asymmetry in …

2. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertensionResearch summary

   Research summaries · alzhub.org/study/perivascular-macrophages-mediate-the-neurovascular-and-cognitive-27841763

   … PVMs are critical in driving the alterations in neurovascular regulation and attendant cognitive impairment in mouse models of hypertension. This effect was mediated by an increase in blood-brain barrier permeability that allowed …

3. Tau seeds from Alzheimer's disease brains trigger tau spread in macaques while oligomeric-Aβ mediates pathology maturationResearch summary

   Research summaries · alzhub.org/study/tau-seeds-from-alzheimer-s-disease-brains-trigger-tau-spread-in-38148705

   … of oligomeric Aβ in driving the maturation and toxicity of tau pathology. This work establishes a novel animal model of early sporadic AD that is closer to the human pathology. Results Pathological tau injection increased …

4. APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-βResearch summary

   Research summaries · alzhub.org/study/apoe4-impact-on-soluble-and-insoluble-tau-pathology-is-mostly-39817469

   … the primacy of Aβ in driving tau pathology. Although APOE4 is strongly associated with amyloid-β (Aβ), its relationship with tau accumulation is less understood. Studies evaluating the role of APOE4 on tau accumulation showed …

5. Amyloid-β and Tau at the Crossroads of Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/amyloid-and-tau-at-the-crossroads-of-alzheimer-s-disease-32096039

   … amyloid-β is the predominant driving factor in AD development. Nonetheless, more recent advances in imaging analysis, biomarkers and mouse models are now redefining this original hypothesis, as it is likely amyloid-β, tau and …

6. BAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathologyResearch summary

   Research summaries · alzhub.org/study/bad-mediated-neuronal-apoptosis-and-neuroinflammation-contribute-to-34430820

   … to AD pathologies by driving neuronal apoptosis and neuroinflammation but suppressing microglial phagocytosis of Aβ, suggesting that BAD is a potential therapeutic target for AD. BAD pro-apoptotic activity is significantly …

7. Human microglia show unique transcriptional changes in Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/human-microglia-show-unique-transcriptional-changes-in-alzheimer-s-37248328

   … inferred gene networks driving observed transcriptomic change, and apply trajectory analysis to reveal the putative relationships between microglial phenotypes. We identify microglial phenotypes more prevalent in AD cases …

8. Integrating Machine Learning and Environmental and Genetic Risk Factors for the Early Detection of Preclinical Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/integrating-machine-learning-and-environmental-and-genetic-risk-39969227

   … a week. Naturalistic driving data were collected using a commercial datalogger. Biomarker positivity was determined via amyloid pathology using cerebrospinal fluid and positron emission tomography imaging. ADI was captured based …

9. New pharmacologic agents for insomnia and hypersomniaResearch summary

   Research summaries · alzhub.org/study/new-pharmacologic-agents-for-insomnia-and-hypersomnia-32890017

   … and possible next-day driving impairment, should be discussed for all agents used for insomnia, including orexin receptor antagonists. Novel agents also are available for hypersomnia and there are options beyond traditional …

10. P-tau217 and other blood biomarkers of dementia: variation with time of dayResearch summary

    Research summaries · alzhub.org/study/p-tau217-and-other-blood-biomarkers-of-dementia-variation-with-time-39271655

    … Currently, the factors driving this diurnal variation are unknown and could be related to sleep, circadian mechanisms, activity, posture, or meals. Overall, this work implies that the time of day of sample collection may be …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.